FR2781797B1 - Derives de piperazine antidiabetiques, leurs procedes de preparation et compositions pharmaceutiques les contenant - Google Patents

Derives de piperazine antidiabetiques, leurs procedes de preparation et compositions pharmaceutiques les contenant

Info

Publication number
FR2781797B1
FR2781797B1 FR9809660A FR9809660A FR2781797B1 FR 2781797 B1 FR2781797 B1 FR 2781797B1 FR 9809660 A FR9809660 A FR 9809660A FR 9809660 A FR9809660 A FR 9809660A FR 2781797 B1 FR2781797 B1 FR 2781797B1
Authority
FR
France
Prior art keywords
antidiabetic
processes
preparation
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9809660A
Other languages
English (en)
Other versions
FR2781797A1 (fr
Inventor
Gerard Moinet
Dominique Marais
Didier Mesangeau
Lilianne Doare
Micheline Kergoat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
LIPHA SAS
LIPHA Liyonnaise Industrielle Pharmaceutique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9809660A priority Critical patent/FR2781797B1/fr
Application filed by LIPHA SAS, LIPHA Liyonnaise Industrielle Pharmaceutique filed Critical LIPHA SAS
Priority to PCT/EP1999/005111 priority patent/WO2000006558A1/fr
Priority to BR9913149-8A priority patent/BR9913149A/pt
Priority to PL99345735A priority patent/PL345735A1/xx
Priority to HU0102830A priority patent/HUP0102830A3/hu
Priority to SK114-2001A priority patent/SK1142001A3/sk
Priority to US09/744,693 priority patent/US6376495B1/en
Priority to RU2001104880/04A priority patent/RU2208610C2/ru
Priority to JP2000562361A priority patent/JP2002521477A/ja
Priority to KR1020017002107A priority patent/KR20010072775A/ko
Priority to CA002338694A priority patent/CA2338694A1/fr
Priority to AU51609/99A priority patent/AU752993B2/en
Priority to EP99936561A priority patent/EP1100790A1/fr
Priority to ARP990103735A priority patent/AR020646A1/es
Priority to TW088112795A priority patent/TW472046B/zh
Publication of FR2781797A1 publication Critical patent/FR2781797A1/fr
Application granted granted Critical
Publication of FR2781797B1 publication Critical patent/FR2781797B1/fr
Priority to NO20010469A priority patent/NO20010469L/no
Priority to ZA200102495A priority patent/ZA200102495B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
FR9809660A 1998-07-28 1998-07-28 Derives de piperazine antidiabetiques, leurs procedes de preparation et compositions pharmaceutiques les contenant Expired - Fee Related FR2781797B1 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
FR9809660A FR2781797B1 (fr) 1998-07-28 1998-07-28 Derives de piperazine antidiabetiques, leurs procedes de preparation et compositions pharmaceutiques les contenant
EP99936561A EP1100790A1 (fr) 1998-07-28 1999-07-17 Derives antidiabetiques de piperazine, leurs procedes de preparation et compositions les contenant
PL99345735A PL345735A1 (en) 1998-07-28 1999-07-17 Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them
HU0102830A HUP0102830A3 (en) 1998-07-28 1999-07-17 Antidiabetic piperazine derivatives, process for their preparation and pharmaceutical compositions containing them
SK114-2001A SK1142001A3 (en) 1998-07-28 1999-07-17 Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them
US09/744,693 US6376495B1 (en) 1998-07-28 1999-07-17 Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them
RU2001104880/04A RU2208610C2 (ru) 1998-07-28 1999-07-17 Пиперазиновые производные, способ их получения и содержащая их композиция
JP2000562361A JP2002521477A (ja) 1998-07-28 1999-07-17 抗糖尿病活性を有するピペラジンとその製造方法およびそれを含有する組成物
PCT/EP1999/005111 WO2000006558A1 (fr) 1998-07-28 1999-07-17 Derives antidiabetiques de piperazine, leurs procedes de preparation et compositions les contenant
CA002338694A CA2338694A1 (fr) 1998-07-28 1999-07-17 Derives antidiabetiques de piperazine, leurs procedes de preparation et compositions les contenant
AU51609/99A AU752993B2 (en) 1998-07-28 1999-07-17 Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them
BR9913149-8A BR9913149A (pt) 1998-07-28 1999-07-17 Derivados de piperazina antidiabéticos, processos para sua preparação e composições contendo os mesmos
KR1020017002107A KR20010072775A (ko) 1998-07-28 1999-07-17 항당뇨병성 피페라진 유도체, 이들 제제의 제조방법 및이를 함유하는 조성물
ARP990103735A AR020646A1 (es) 1998-07-28 1999-07-28 Derivados de la piperazina con efecto antidiabetico, los procedimientos para su preparacion, las composiciones farmaceuticas que los contieneny el empleo de los mismos para preparar un medicamento
TW088112795A TW472046B (en) 1998-07-28 1999-09-23 Antidiabetic piperazine derivatives, process for their preparation and compositions containing them
NO20010469A NO20010469L (no) 1998-07-28 2001-01-26 Antidiabetiske piperazinderivater, fremgangsmåter for deres fremstilling og preparater inneholdende dem
ZA200102495A ZA200102495B (en) 1998-07-28 2001-03-27 Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9809660A FR2781797B1 (fr) 1998-07-28 1998-07-28 Derives de piperazine antidiabetiques, leurs procedes de preparation et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
FR2781797A1 FR2781797A1 (fr) 2000-02-04
FR2781797B1 true FR2781797B1 (fr) 2000-11-03

Family

ID=9529125

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9809660A Expired - Fee Related FR2781797B1 (fr) 1998-07-28 1998-07-28 Derives de piperazine antidiabetiques, leurs procedes de preparation et compositions pharmaceutiques les contenant

Country Status (17)

Country Link
US (1) US6376495B1 (fr)
EP (1) EP1100790A1 (fr)
JP (1) JP2002521477A (fr)
KR (1) KR20010072775A (fr)
AR (1) AR020646A1 (fr)
AU (1) AU752993B2 (fr)
BR (1) BR9913149A (fr)
CA (1) CA2338694A1 (fr)
FR (1) FR2781797B1 (fr)
HU (1) HUP0102830A3 (fr)
NO (1) NO20010469L (fr)
PL (1) PL345735A1 (fr)
RU (1) RU2208610C2 (fr)
SK (1) SK1142001A3 (fr)
TW (1) TW472046B (fr)
WO (1) WO2000006558A1 (fr)
ZA (1) ZA200102495B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1350452A (zh) * 1999-05-13 2002-05-22 盐野义制药株式会社 糖尿病的预防或治疗药
FR2829765A1 (fr) * 2001-09-14 2003-03-21 Lipha Derives imidazolylalkoxylarylalcanoiques leurs applications en therapeutique
US8097610B2 (en) 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
JP2008239616A (ja) * 2007-02-28 2008-10-09 Iyaku Bunshi Sekkei Kenkyusho:Kk Ｈｄｌ上昇剤
CN102485717B (zh) 2010-12-06 2015-12-02 中国人民解放军军事医学科学院毒物药物研究所 噻唑胺衍生物及其作为抗小rna病毒感染药物的用途
FR2976943B1 (fr) * 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
FR2976942B1 (fr) 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
FR2999427B1 (fr) * 2012-12-17 2015-01-30 Metabolys Composition et kit comprenant des derives de piperazine et de la metformine, leur utilisation dans le traitement du diabete

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3277094A (en) * 1965-05-10 1966-10-04 Ciba Geigy Corp Piperazine derivatives
US3951983A (en) * 1970-11-10 1976-04-20 Pfizer Inc. Phenoxypropanolpiperazines
DE3564683D1 (en) * 1984-08-07 1988-10-06 Cortial 4-(arylpiperazinylethylaminoethoxy) phenol derivatives, process for their preparation and their therapeutical application
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists

Also Published As

Publication number Publication date
RU2208610C2 (ru) 2003-07-20
BR9913149A (pt) 2003-01-21
PL345735A1 (en) 2002-01-02
CA2338694A1 (fr) 2000-02-10
SK1142001A3 (en) 2001-09-11
KR20010072775A (ko) 2001-07-31
EP1100790A1 (fr) 2001-05-23
US6376495B1 (en) 2002-04-23
FR2781797A1 (fr) 2000-02-04
ZA200102495B (en) 2002-09-27
AU752993B2 (en) 2002-10-03
HUP0102830A2 (hu) 2001-12-28
AU5160999A (en) 2000-02-21
TW472046B (en) 2002-01-11
WO2000006558A1 (fr) 2000-02-10
HUP0102830A3 (en) 2002-12-28
JP2002521477A (ja) 2002-07-16
NO20010469D0 (no) 2001-01-26
NO20010469L (no) 2001-01-26
AR020646A1 (es) 2002-05-22

Similar Documents

Publication Publication Date Title
MA26479A1 (fr) Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26453A1 (fr) Derives de 6-phenylpyridyl-2 amine et compositions pharmaceutiques les contenant
MA26537A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant.
DZ2964A1 (fr) Diphénylurées substituées nouvelles, et compositions pharmaceutiques les contenant.
EE200200409A (et) 1,3-dihüdro-2H-indool-2-ooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
MA26499A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
FR2789079B3 (fr) Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
NO20001409D0 (no) Karboksamidotiazolderivater, fremgangsmåte for fremstilling derav og farmasøytiske blandinger
FI963566A0 (fi) Uusia piperatsiinijohdoksia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä koostumuksia
EE200000613A (et) Kinoliini derivaadid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
MA26468A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26548A1 (fr) Compositions pharmaceutiques topiques contenant des derives de resorcinol.
EE04578B1 (et) Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nendesolvaatide suu kaudu manustamiseks
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
FR2735777B1 (fr) Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
MA26490A1 (fr) Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant.
HUP0104922A2 (en) New piperazine and piperidine derivatives and pharmaceutical compositions containing them and processes for their preparation
HUP0105073A3 (en) 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them
MA26519A1 (fr) Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
EE9800426A (et) Asendatud 2,4-tiasolidiindiooni derivaadid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
MA26791A1 (fr) Derives de la purine, leur procede de preparation, et compositions pharmaceutiques les contenant.
FR2687401B1 (fr) Derives de la 1,4-dialkylpiperazine, procedes d'obtention et compositions pharmaceutiques les contenant.
FR2781797B1 (fr) Derives de piperazine antidiabetiques, leurs procedes de preparation et compositions pharmaceutiques les contenant
FR2773801B1 (fr) Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
FR2772761B1 (fr) Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
ST Notification of lapse